FDA's August 2026 peptide letters and Lilly's six lawsuits

In August 2026 the two parties with the most power over the retatrutide gray market moved within twelve days of each other. Eli Lilly sued six sellers on 12 August. FDA dated five warning letters to peptide vendors on 24 August. Neither accepted "research use only" as an answer.

The documents read like they were written from the same checklist. FDA quoted vendors' code names ("GLP-3R", "GLP-3 RT", "GLP-3 Reta") and wrote "retatrutide" next to each one. It called bacteriostatic water a drug because the vendors sold it for mixing injectables. Lilly's lawyers quoted a seller's "Retatrutide Dosage Calculator", its syringe graphic, and customer reviews about pounds lost. If you buy from a vendor that runs any of those practices, you should know what the regulator and the patent holder now treat as evidence.

What did FDA's August 2026 warning letters say?

All five letters came from CDER's Office of Unapproved Drugs and Labeling Compliance, all are dated 24 August 2026, and all follow one template. FDA reviewed each website in July 2026, found products marketed with claims about the body, and concluded they were "unapproved new drugs" under section 505(a) of the Food, Drug, and Cosmetic Act. Each firm got 15 business days to reply.

Three details stand out.

Code names gave no cover. FDA put the brand name in quotation marks and the molecule in brackets. NuScience's own product title, "GLP-3 RT (Retatrutide) Research Peptide", already did FDA's decoding for it. Our code-name decoder maps the same aliases, and the GLP-3 RT explainer covers why "GLP-3" is not a real receptor class.

The claims FDA quoted were mostly "research" language. Peak Performance wrote that "GLP-3R has been explored for its influence on appetite suppression, energy expenditure, and fat distribution." Royal's blog said retatrutide "may result in up to 24.2% body weight reduction in just 48 weeks." Peptide Partners described "the weight-loss drug Retatrutide." Tex Peptides said "GLP-3 RT may provide superior outcomes compared to GLP-1 or dual agonists alone." FDA treated each as a claim about the human body.

The list went past weight loss. SS-31, tesamorelin and PT-141 appear in all five letters. NuScience's letter is the first FDA letter we have seen that names survodutide and mazdutide, two investigational GLP-1/glucagon agonists from Boehringer Ingelheim and Innovent.

Who did Lilly sue, and in which courts?

Lilly's 12 August release names six defendants. It also says Lilly has referred more than 200 people and entities to regulators and reported more than 14,000 websites, ads, posts and listings in over 100 countries. The release asks payment processors, card networks, platforms and shippers to "cut off the infrastructure enabling this illegal trade."

The claims are state-law unfair-competition counts (Texas common law plus the consumer-protection acts of seven other states), not federal drug-law counts. A private company cannot enforce the Food, Drug, and Cosmetic Act, so Lilly argues that selling an unapproved new drug breaks state law and costs it sales of Mounjaro, Zepbound and Foundayo. The complaints also say FDA has sent "at least 16 warning letters related to retatrutide." That count is Lilly's; we have not recounted it.

What evidence did FDA and Lilly use?

Put the eleven documents side by side and five exhibits recur.

1. Code names. "GLP-3R", "GLP-3 RT", "GLP-3 Reta", "GLP3 (R)", "Reta GLP-3", "RT-3". FDA and Lilly translated every one.
2. Bacteriostatic water sold next to the vial. FDA's footnote in the Peak Performance, Peptide Partners and Tex Peptides letters reads: "you market bacteriostatic water as a solvent for reconstituting your products, thus, providing the means to prepare an injectable drug for human administration."
3. Calculators and mixing guides. NuScience and Royal were cited for a "peptide calculator". Lone Star's calculator promised "the exact tick mark to draw to". Lilly's lawyers wrote that the instructions "are not for researchers" because researchers in a lab "are in fact not permitted" to inject human subjects.
4. Customer voice. Reviews on Google and Trustpilot, TikTok comments, and Reddit. The complaints quote r/Retatrutide and r/Biohacking threads on switching from tirzepatide and on side effects, including a post describing a skin reaction "like tiny mites or something crawling and biting".
5. Consumer retail mechanics. Age gates set at 21, same-day shipping, kit bundles, "2 for $99" offers, and comparisons to approved drugs.

None of the eleven documents relies on lab testing of the vendors' product. The case against each seller was built entirely from its own website and social accounts.

Does "research use only" protect a vendor?

Not on this record. Each FDA letter opens its key footnote with "Despite statements on your product labeling marketing your products 'for research use only'" and then explains why the website said otherwise. Lilly's complaints use the word "pretext". The law firm ArentFox Schiff, in a 18 September 2026 alert, reads the batch the same way: FDA "looks past the label to the net impression of the website as a whole."

A self-described pharma attorney on Reddit put the August sequence more bluntly: "Unauthorized sale of Reta and other GLP-1s may be coming to an end" (r/Biohackers). We cannot confirm the poster's credentials, and the documents do not show an outcome yet. No court has ruled in any of the six cases as of 5 October 2026, and we found no published response to any of the five letters.

This is the same point the Paradigm Peptides prosecution made in criminal court. Its owner admitted the research-use label was false; we covered that in forged COAs and a 70-month sentence.

Which of these practices do our audits already score?

Fewer than you might expect. Our composite weights purity and COA quality at 40%, label accuracy at 25%, shipping at 20% and support at 15% (methodology). It measures whether the vial matches the label and arrives. It does not measure legal exposure.

That gap matters. Peptide Partners publishes Kovera Labs certificates. Our registry holds 11 of them, and the three retatrutide lots with results (RTT2613, RTT202606, RT202607, published June and July 2026) report 99.4% to 99.8% purity, LC-MS identity confirmed and a passing endotoxin screen. Those certificates did not keep the firm out of an FDA letter. Product quality and legal status are separate questions, and a passing COA answers only the first. The full list of ways vendors fail is in our vendor failure taxonomy.

What happened to the vendors afterwards?

We loaded each firm's site, and where possible the exact product URL FDA or Lilly quoted, on 5 October 2026.

The pattern is that pages named in a lawsuit disappeared, while three of the five FDA letter recipients still showed retatrutide eight weeks after the letter date. The Peptide Catalog reported on 13 August, citing CBS News, that Lone Star, Texas Peptides and Aesthetic Envy pulled retatrutide pages on the day of filing. We did not see the CBS report ourselves.

What does this mean if you bought from one of these vendors?

A warning letter is not a recall and says nothing about what was in your vial. FDA did not test these products. What the letters change is the vendor's risk of seizure, injunction or a sudden stop. When a vendor stops, its certificate archive often goes with it, as it did for the three shutdowns in three vendors closed in 12 months.

Three steps cost nothing:

1. Save copies of any certificates for lots you hold, with the retrieval date, and resolve each one on the issuing lab's own server.
2. Search the vendor's company name and domain in FDA's warning letter database.
3. Read the enforcement timeline for the letters that came before this batch.

If you are looking at retatrutide specifically, the where-to-buy page covers the one lawful route that exists today: Lilly's physician-requested expanded access program (NCT07629401), which supplies the drug free to a narrow group of patients.

What we read

The five FDA warning letters dated 24 August 2026, in full, on fda.gov. Lilly's 12 August 2026 release. The complaints against Legendary Peptides, Astra, Lone Star, Texas Peptides and Striker Pharmacy as filed on CourtListener, including image pages we transcribed. ArentFox Schiff's 18 September 2026 alert. Each named firm's website on 5 October 2026. Our own mirror of Kovera Labs certificates. This is a document review, not a first-hand audit.

What we did not read

The Aesthetic Envy complaint (N.D. Cal.). Any vendor response to FDA, none of which we found published. Docket activity after the complaints. The CBS News report of 12 August, which we cite only through a secondary source. FDA's own count of retatrutide letters, which we have not reconciled with Lilly's figure of at least 16.

Sources

• FDA warning letter 735127, Peak Performance Peptides, 24 Aug 2026
• FDA warning letter 734884, Royal Peptides LLC, 24 Aug 2026
• FDA warning letter 733652, NuScience Peptides LLC, 24 Aug 2026
• FDA warning letter 735063, Peptide Partners LLC, 24 Aug 2026
• FDA warning letter 735067, TXP Innovations dba Tex Peptides, 24 Aug 2026
• Eli Lilly, release on six retatrutide lawsuits, 12 Aug 2026
• Eli Lilly v. Legendary Peptides, E.D. Tex. 1:26-cv-00347, complaint
• Eli Lilly v. Astra LLC, W.D. Tex. 5:26-cv-05147, complaint
• Eli Lilly v. Lone Star Peptide Co., S.D. Tex. 4:26-cv-06562, complaint
• Eli Lilly v. Texas Peptides Inc., W.D. Tex. 5:26-cv-05146, complaint
• Eli Lilly v. Striker Pharmacy, S.D. Tex. 4:26-cv-06563, complaint
• ArentFox Schiff, RUO-ined, 18 Sep 2026
• Lilly Medical, retatrutide expanded access (NCT07629401)
• The Peptide Catalog, Lilly sues six retatrutide sellers, 13 Aug 2026 (secondary)
• r/Biohackers, pharma attorney thread, Aug 2026